It is noteworthy that decreased MAP2 expression at synapses precedes the appearance of AD plaques, suggesting that MAP2 alterations may serve as early markers of synaptic pathology and cognitive impairment [44]. The gene discussed is MAP2; the disease is Cognitive impairment.